Clinical Trials for Small Cell Lung Cancer

A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable/metastatic solid tumors harboring KRAS G12V/D/C/R/A or G13D mutations or KRAS amplification (ECOG 0–1, measurable disease) receive IV ASP5834, a first‑in‑human pan‑KRAS targeted protein degrader designed to eliminate multiple KRAS variants; dose-expansion includes PDAC, NSCLC, and other non-CRC tumors. Separate colorectal cancer cohorts test ASP5834 combined with panitumumab in KRAS‑mutant mCRC after standard therapies.

ClinicalTrials.gov ID: NCT07094204

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with advanced/metastatic solid tumors lacking standard options; dose-escalation all-comers followed by expansion in biomarker-selected cohorts including NSCLC with YES1 or TYMS amplification or FAT1 mutation, renal cancer or mesothelioma with NF2 mutation, and other tumors with NF2/FAT1/LATS1 mutations or TYMS/YAP1/YES1/TAZ1 amplifications. Treatment is NXP900, an oral conformation-selective SRC family kinase inhibitor with high potency against YES1/SRC, given as monotherapy.

ClinicalTrials.gov ID: NCT05873686

A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants With Advanced or Metastatic Select Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, unresectable advanced/metastatic solid tumors (NSCLC, HNSCC, ESCC, left‑sided CRC) receive ALX2004 monotherapy, an investigational EGFR‑targeted antibody–drug conjugate carrying a topoisomerase I inhibitor payload designed for bystander effect. Excludes candidates for curative local therapy, rapidly progressive disease, short life expectancy, and prior exposure to topoisomerase I inhibitor ADCs.

ClinicalTrials.gov ID: NCT07085091

A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic solid tumors harboring KRAS alterations (any missense mutation or amplification) and no standard options receive the investigational oral pan‑KRAS inhibitor AMG 410 (dual-state, noncovalent inhibitor selective over HRAS/NRAS) as monotherapy or combined with pembrolizumab (solid tumors) or panitumumab (CRC/PDAC). Includes multiple tumor types (e.g., NSCLC, CRC, PDAC) with measurable disease and ECOG 0–1; treatment continues until progression or intolerance.

ClinicalTrials.gov ID: NCT07094113

An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with DLL3-expressing advanced/metastatic neuroendocrine carcinomas (including SCLC, LCNEC, and extrapulmonary NEC; predominant ≥50% neuroendocrine component) receive peluntamig (PT217), a bispecific anti-DLL3/CD47 IgG designed to promote macrophage phagocytosis and ADCC, as monotherapy or combined with carboplatin/etoposide, paclitaxel, and/or atezolizumab. Cohorts include relapsed/refractory disease and line-specific settings such as platinum-sensitive second line and ES-SCLC first-line or post-induction with atezolizumab.

ClinicalTrials.gov ID: NCT05652686

A Phase 1 Dose Escalation and Expansion Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 in Subjects With Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced/metastatic c‑Kit–expressing solid tumors (including GIST, SCLC, adenoid cystic carcinoma, uveal melanoma, NETs, chromophobe or clear‑cell RCC) who have progressed after or are ineligible/intolerant to standard therapy receive NN3201, an IV c‑Kit (CD117)–targeted antibody‑drug conjugate delivering MMAE every 3 weeks. Expansion cohorts include GIST (post‑imatinib), SCLC, and other c‑Kit–positive tumors to assess safety and preliminary efficacy.

ClinicalTrials.gov ID: NCT06805825

A Phase 1a/b, Open-label, Dose-escalation Study of the Safety, Pharmacokinetics, and Initial Efficacy of 225Ac-ABD147 in Patients With Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma of the Lung Following Platinum-based Chemotherapy

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced/metastatic small cell lung cancer or large cell neuroendocrine carcinoma post–platinum chemotherapy receive IV 225Ac-ABD147, a DLL3-targeted VHH-Fc alpha-emitting radiopharmaceutical delivering actinium-225 to DLL3-expressing tumors. Dose-escalation/expansion evaluates safety, PK/dosimetry, and preliminary efficacy; stable treated brain metastases allowed.

ClinicalTrials.gov ID: NCT06736418

A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with progressive, unresectable/metastatic, SSTR2-positive NETs (primarily GEP-NETs; also bronchial NETs and pheo/para) who are PRRT-naïve and ECOG 0–2. Investigational therapy is [212Pb]VMT-α-NET, an SSTR2-targeted alpha-emitting radiopharmaceutical (212Pb/212Bi/212Po) given up to four cycles every ~8 weeks with amino acid renal protection; early cohorts include a 203Pb imaging microdose for dosimetry.

ClinicalTrials.gov ID: NCT05636618

A Multi-Center, Open Label, Phase 1/2 Study of CP-383, in Patients With Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic solid tumors lacking effective standard options (broad basket with prioritized cohorts such as CRC, SCLC, HNSCC, NSCLC, pancreatic, and bladder; some genomically enriched) receive oral single‑agent CP-383 in dose escalation and tumor‑specific expansions. CP-383 is a first‑in‑class small molecule designed to modulate lipid‑binding pockets on oncogenic proteins (exact target undisclosed).

ClinicalTrials.gov ID: NCT07030257

A Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic urothelial/bladder cancer, NSCLC, HNSCC, esophageal cancer, or pancreatic adenocarcinoma (ECOG 0–1) receive PF-08046876, an ITGB6-targeted antibody–drug conjugate delivering a topoisomerase I payload, as IV monotherapy after prior standard therapy (≤2 prior lines in Part 2). Dose escalation/optimization and tumor-specific expansions assess safety, PK, and preliminary activity; excludes prior camptothecin/topo I ADC exposure and significant GI or pulmonary comorbidities.

ClinicalTrials.gov ID: NCT07090499